Chinook Therapeutics Inc (KDNY) Stock
KDNY is no longer traded. Chinook Therapeutics was acquired by Novartis (NVS) on August 11, 2023.
Each KDNY share was exchanged for $40.00 in cash plus a contingent value right of up to $4.00. Prices on this page are historical; the last trade was August 10, 2023 at $40.39.
See Novartis (NVS) stock →Chinook Therapeutics stock price history
KDNY final trading statistics
- Final close
- $40.39
- Final trading day
- Aug 10, 2023
- Market cap at delisting
- $2.71B
- Shares outstanding
- 67.05M
- Final 52-week range
- $18.34 – $40.51
- Avg. volume (final 3 mo.)
- 2,063,462
- All-time high (split-adj.)
- $214.00 · Apr 2015
- All-time low (split-adj.)
- $4.99 · Dec 2019
- Return since IPO
- -80.8%
- Beta
- 0.67
- Book value / share
- $5.32
- Price / book
- 7.59
Chinook Therapeutics annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2022 | $6.13M | -$184.6M | -$2.88 |
| FY2021 | $51.62M | -$101.3M | -$2.93 |
| FY2020 | $827.0K | -$81.6M | -$3.64 |
| FY2019 | $17.26M | -$46.9M | -$4.80 |
| FY2018 | $15.09M | -$95.4M | -$6.05 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Chinook Therapeutics Inc
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington. As of August 11, 2023, Chinook Therapeutics, Inc. operates as a subsidiary of Novartis AG.
Chinook Therapeutics stock FAQ
What happened to Chinook Therapeutics stock?
Chinook Therapeutics was acquired by Novartis (NVS) on August 11, 2023. Shareholders received $40.00 in cash plus a contingent value right of up to $4.00 for each share. KDNY stock stopped trading on the Nasdaq, with a final close of $40.39 on August 10, 2023.
What did Chinook Therapeutics shareholders receive?
Each KDNY share was converted into $40.00 in cash plus a contingent value right of up to $4.00. The deal was valued at about $3.5 billion.
Is KDNY stock still trading?
No. KDNY was delisted from the Nasdaq on August 11, 2023 and no longer trades on a U.S. exchange.
What was the last price of KDNY stock?
KDNY closed at $40.39 on its final trading day, August 10, 2023, for a market value of about $2.71B.
What were Chinook Therapeutics's revenue and earnings in its last full fiscal year?
Chinook Therapeutics reported revenue of $6.13M and net income of -$184.6M in fiscal 2022, its last full year as a public company.
When did Chinook Therapeutics go public?
Chinook Therapeutics Inc stock began trading on April 15, 2015.